Erythropoietin variants

The challenge of FOPs demonstrating similar quality, safety, and efficacy to the innovator product relates to the poor predictability of physicochemical characteristics and biologic activity. For example, there are several different interferon-a and erythropoietin a and P products currently on the market. These variants are characterized by differences in sequence, glycosylation pattern, and in vitro measures of specific activity however, their clinical safety and efficacy profiles are considered similar [20],... 

Bressolle et al. used two variants of the indirect response models, stimulation of synthesis and of degradation processes, for modeling the effect of recombinant erythropoietin on the two response parameters free ferritin concentration (Fr) and soluble transferrin receptor concentration [83]. While erythropoietin reduces Fr, it increases Tfr (Fig. 7). The temporal change in both response variables can be described by the following equations ... 

Albumin alpha(l)-acid glycoprotein Albumin lysozyme ribonuclease a Amyloid precursor protein Beta lactoglobulin Botulinum neurotoxin Erythropoietin Erythropoietin Hemoglobin variants, mouse Hemoglobin variants, human Hemoglobin, globin chains HIV-1 reverse transcriptase Insulin trypsin... 

TNF receptor linked to IgGl 3.6 billion) and four variants of erythropoietin, Aranesp, Procrit, EPOGEN, and NeoRecormon together accounting for 10.8 billion (Lawrence 2006). 

---